Page last updated: 2024-10-30

mesalamine and Local Neoplasm Recurrence

mesalamine has been researched along with Local Neoplasm Recurrence in 3 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Louis, E1
Paridaens, K1
Al Awadhi, S1
Begun, J1
Cheon, JH1
Dignass, AU1
Magro, F1
Márquez, JR1
Moschen, AR1
Narula, N1
Rydzewska, G1
Freddi, MJ1
Travis, SP1
Ishikawa, H1
Mutoh, M1
Sato, Y1
Doyama, H1
Tajika, M1
Tanaka, S1
Horimatsu, T1
Takeuchi, Y1
Kashida, H1
Tashiro, J1
Ezoe, Y1
Nakajima, T1
Ikematsu, H1
Hori, S1
Suzuki, S1
Otani, T1
Takayama, T1
Ohda, Y1
Mure, K1
Wakabayashi, K1
Sakai, T1
Papaioannou, D1
Rafia, R1
Stevenson, MD1
Stevens, JW1
Evans, P1

Reviews

1 review available for mesalamine and Local Neoplasm Recurrence

ArticleYear
Trabectedin for the treatment of relapsed ovarian cancer.
    Health technology assessment (Winchester, England), 2011, Volume: 15 Suppl 1

    Topics: Antineoplastic Agents, Alkylating; Dioxoles; Doxorubicin; Female; Humans; Mesalamine; Meta-Analysis

2011

Trials

1 trial available for mesalamine and Local Neoplasm Recurrence

ArticleYear
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    The lancet. Gastroenterology & hepatology, 2021, Volume: 6, Issue:6

    Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control St

2021

Other Studies

1 other study available for mesalamine and Local Neoplasm Recurrence

ArticleYear
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.
    BMJ open gastroenterology, 2022, Volume: 9, Issue:1

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerat

2022